Companies · Biotechnology

Scorpius Holdings, Inc.

MORRISVILLE · Biotechnology

Diligence memoA one-page analyst read on Scorpius Holdings, Inc. — recommendation, valuation, rhythm, risks.
$23.6M
Total raised · real
7
Rounds
1.7×
Latest step-up
Top 31%
Sector rank · raised
Series A
Latest stage · inferred · Wed Feb 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Scorpius Holdings, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.25× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Active
  • Last raise 17 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Scorpius Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
16.7 yr record
Peak capital year was 2024 with $13.4M across 1 filings.
Market position
ahead of 70% of Biotechnology peers
Capital scale is ahead of 70% of Biotechnology peers; modeled value is above 8% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2024: $13.4M across 1 filings.
  • Largest single filing was $13.4M on 2024-12-06.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Scorpius Holdings, Inc. is one of 4293 Biotechnology companies tracked from MORRISVILLE. By capital raised it ranks in the upper tier (ahead of 70% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-02-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2009-11-03 Raised $250K (real) Modeled valuation $14M (est)Pre-Seed2009Seed · 2011-12-20 Raised $2.8M (real) Modeled valuation $126M (est)Seed2011Series A · 2013-03-25 Raised $5.1M (real) Modeled valuation $183M (est)Series A2013Series A · 2017-04-28 Raised $500K (real) Modeled valuation $18M (est)Series A2017Series A · 2024-12-06 Raised $13M (real) Modeled valuation $57M (est)Series A2024Series A · 2025-01-30 Raised $600K (real) Modeled valuation $2.4M (est)Series A2025Series A · 2025-02-12 Raised $1.0M (real) Modeled valuation $3.9M (est)Series A2025+$2.8M+$5.1M+$500K+$13M+$600K+$1.0MCumulative $24M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$250K · 2009
Seed$2.8M · 2011
Series A$5.1M · 2013
Series A extension$500K · 2017
Series A extension$13.4M · 2024
Series A extension$600K · 2025
Series A extension$1.0M · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$3.9M
Base estimate est.
$1.1M
Conservative case
$7.3M
Upside case
$4.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $13.8M · 2009-11-032009Seed · modeled $125.6M · 2011-12-20Series A · modeled $182.6M · 2013-03-25Series A · modeled $18.1M · 2017-04-28Series A · modeled $57.1M · 2024-12-06Series A · modeled $2.4M · 2025-01-30Series A · modeled $3.9M · 2025-02-122025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
1.4 yr
Elapsed time used
1.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
31 mo
Avg between rounds
$1.5M/yr
Capital velocity
16.7 yr
On record since
2009
First round
7
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.3× above median
This company$23.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.9M
Sector median$64.2M

Raised more than 70% of sector peers (real $). Modeled value above 8% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #134 of 157.

This companyCohort peer
$1.0M$10.0M$100.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.6M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.5M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.7M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.2M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.3M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.2M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.9M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.8M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)Scorpius Holdings, Inc. (this company) Raised $23.6M · modeled $3.9M (est)Scorpius Holdings, Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.6M3.75×
Edesa Biotech, Inc.Series A$36.9M$58.5M3.74×
4DMedical LtdSeries A$15.0M$50.7M3.24×
Arialys Therapeutics, Inc.Series A$29.1M$49.2M3.14×
Nuclein, LLCSeries A$34.5M$48.3M3.09×
Phantom Neuro Inc.Series A$15.4M$45.7M2.92×
Circulate Health, Inc.Series A$13.0M$43.3M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.2M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.61×
ENDRA Life Sciences Inc.Series A$26.8M$40.9M2.61×
Medici Therapeutics, Inc.Series A$14.8M$39.8M2.54×
Onconetix, Inc.Series A$22.0M$37.7M2.41×
Scorpius Holdings, Inc. this companySeries A$23.6M$3.9M0.25×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$250K2009-11-03$1.4M$13.8M85%
Seed$2.8M2011-12-20$14.1M$125.6M85%
Series A$5.1M2013-03-25$23.0M$182.6M85%
Series A$500K2017-04-28$2.3M$18.1M90%
Series A$13.4M2024-12-06$60.9M$57.1M90%
Series A$600K2025-01-30$2.7M$2.4M90%
Series A$1.0M2025-02-12$4.5M$3.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$250K2009-11-03
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$2.8M2011-12-20
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 11.3× larger than the prior — scaling up.
    • 3 investors on this round.
  3. Series A$5.1M2013-03-25
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 1.8× larger than the prior — scaling up.
    • 20 investors on this round.
  4. Series A$500K2017-04-28
    • Raised again after 49 mo — slower than the ~14 mo sector norm.
    • Round 10.1× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 45 investors on this round.
  5. Series A$13.4M2024-12-06
    • Raised again after 91 mo — slower than the ~14 mo sector norm.
    • Round 26.8× larger than the prior — scaling up.
    • 2 investors on this round.
  6. Series A$600K2025-01-30
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 22.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  7. Series A$1.0M2025-02-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2027 ~Q3
Modeled next raise · ~31mo cadence
$1.7M
Modeled next size est.range $1.1M$2.7M
1.7×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Edward Smith4 other2011-12
JEFFREY WOLF3 other2009-11
John K. A. Prendergast1 other2017-04
John Prendergast1 other2024-12
Ann Rosar2017-04
Edward Byron Smith, III2013-03
Jeffrey Alan Wolf2013-03
Jeffrey Hutchins2017-04
Jeff Wolf2024-12
Jennifer Lynn Harris2013-03
John James Monahan2013-03
JOHN MONAHAN2009-11
Michael James Kharitonov2013-03
MICHAEL KHARITONOV2009-11
PAUL BELSKY2009-11
Paul Marc Belsky2013-03
Sandra Leta Silberman2013-03
Scott Katzman2011-12
TAFFY WILLIAMS2009-11
Vadim Leta Deyev2013-03
William Ostrander2024-12
Registry & provenance

Scorpius Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1476963
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Synthetic Biologics, Inc.BiotechnologySeries A$48.0M$36.9Mnetwork1 shared operator · same sector · same stage
EnteroBiotix LTDBiotechnologySeries A$23.2M$4.4Msame sector · same stage
Aethlon Medical IncBiotechnologySeries A$25.1M$5.7Msame sector · same stage
Electrochemical Oxygen Concepts IncBiotechnologySeries A$21.4M$4.5Msame sector · same stage
NEUROONE MEDICAL TECHNOLOGIES CorpBiotechnologySeries A$21.2M$1.4Msame sector · same stage
Cardio Flow, Inc.BiotechnologySeries A$20.8M$2.1Msame sector · same stage
Alpha Cognition Inc.BiotechnologySeries A$27.6M$1.6Msame sector · same stage
Seelos Therapeutics, Inc.BiotechnologySeries A$27.7M$5.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioNADrx Holdings, Inc.BiotechnologyPre-Seed$748K86%
Torus Biosystems, Inc.BiotechnologySeries B$707.2M85%
NERx Biosciences, Inc.BiotechnologyPre-Seed$4.8M85%
SELLAS Life Sciences Group, Inc.BiotechnologySeries B$148.8M84%
Attralus, Inc.BiotechnologySeries D+$709.1M84%
BioHSV Holdings, Inc.BiotechnologySeed$33.5M84%
Batu Biologics, Inc.BiotechnologyPre-Seed$28.0M84%
Stabilux Biosciences, Inc.BiotechnologyPre-Seed$2.9M84%
Frequently asked
How much funding has Scorpius Holdings, Inc. raised?
Scorpius Holdings, Inc. has raised approximately $23.6M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is Scorpius Holdings, Inc.'s estimated valuation?
Provath's modeled valuation for Scorpius Holdings, Inc. is approximately $3.9M (modeled range $1.1M–$7.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Scorpius Holdings, Inc. at?
Scorpius Holdings, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Feb 12.
What does Scorpius Holdings, Inc. do and where is it based?
Scorpius Holdings, Inc. operates in the Biotechnology sector, based in MORRISVILLE.
Explore related

See where Scorpius Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Scorpius Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.